Switch theme
Sign up to access all valuation multiples
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
1994
82.9K+
LTM Revenue $53.1B
LTM EBITDA $15.9B
$135B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sanofi has a last 12-month revenue (LTM) of $53.1B and a last 12-month EBITDA of $15.9B.
In the most recent fiscal year, Sanofi achieved revenue of $52.2B and an EBITDA of $13.0B.
Sanofi expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sanofi valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $53.1B | XXX | $52.2B | XXX | XXX | XXX |
| Gross Profit | $37.4B | XXX | $36.6B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $15.9B | XXX | $13.0B | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $14.0B | XXX | $11.1B | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $11.1B | XXX | $6.5B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $10.1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, Sanofi's stock price is EUR 83 (or $98).
Sanofi has current market cap of EUR 101B (or $119B), and EV of EUR 114B (or $135B).
See Sanofi trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $135B | $119B | XXX | XXX | XXX | XXX | $8.96 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, Sanofi has market cap of $119B and EV of $135B.
Sanofi's trades at 2.6x EV/Revenue multiple, and 10.4x EV/EBITDA.
Equity research analysts estimate Sanofi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sanofi has a P/E ratio of 10.8x.
See valuation multiples for Sanofi and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $119B | XXX | $119B | XXX | XXX | XXX |
| EV (current) | $135B | XXX | $135B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.5x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 12.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.8x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | 14.0x | XXX | 19.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSanofi's last 12 month revenue growth is 5%
Sanofi's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.3M for the same period.
Sanofi's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sanofi's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sanofi and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sanofi acquired XXX companies to date.
Last acquisition by Sanofi was XXXXXXXX, XXXXX XXXXX XXXXXX . Sanofi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sanofi founded? | Sanofi was founded in 1994. |
| Where is Sanofi headquartered? | Sanofi is headquartered in France. |
| How many employees does Sanofi have? | As of today, Sanofi has 82.9K+ employees. |
| Who is the CEO of Sanofi? | Sanofi's CEO is Mr. Paul Hudson. |
| Is Sanofi publicy listed? | Yes, Sanofi is a public company listed on PAR. |
| What is the stock symbol of Sanofi? | Sanofi trades under SAN ticker. |
| When did Sanofi go public? | Sanofi went public in 1999. |
| Who are competitors of Sanofi? | Similar companies to Sanofi include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sanofi? | Sanofi's current market cap is $119B |
| What is the current revenue of Sanofi? | Sanofi's last 12 months revenue is $53.1B. |
| What is the current revenue growth of Sanofi? | Sanofi revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Sanofi? | Current revenue multiple of Sanofi is 2.5x. |
| Is Sanofi profitable? | Yes, Sanofi is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sanofi? | Sanofi's last 12 months EBITDA is $15.9B. |
| What is Sanofi's EBITDA margin? | Sanofi's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Sanofi? | Current EBITDA multiple of Sanofi is 8.5x. |
| What is the current FCF of Sanofi? | Sanofi's last 12 months FCF is $9.7B. |
| What is Sanofi's FCF margin? | Sanofi's last 12 months FCF margin is 18%. |
| What is the current EV/FCF multiple of Sanofi? | Current FCF multiple of Sanofi is 14.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
